Janssen turns to Danish startup for pill to replace the need to inject drugs

Danish biotech firm Biograil, founded by two former Egalet researchers, has entered a partnership with major pharmaceutical company Janssen and is poised to raise new capital.

Biograil CEO Karsten Lindhardt and CTO Nikolaj Skak. Photo: Biograil / PR

In the beginning of 2020, when MedWatch interviewed the people behind the young biotech firm Biograil, they indicated that they were looking for partners within the pharmaceutical industry. Now – just under a year later – they managed to poach the first one.

This week Biograil presents the announcement that it has entered into a collaboration with the pharmaceutical leg of the giant Johnson & Johnson – Janssen.

Read this article for free

Register with your E-mail.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

Related articles